Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

NCT06712030 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Interventions

DRUG: Sacubitril / Valsartan

Sponsor

Puerta de Hierro University Hospital